Families Say Animal Studies Back Their Claims In Zofran MDL

Law360, New York (January 6, 2016, 3:38 PM EST) -- Families who claim that GlaxoSmithKline’s “off label” promotion of its anti-nausea drug Zofran for morning sickness led to birth defects urged the Massachusetts federal judge overseeing the multidistrict litigation on Wednesday not to dismiss their claims, pointing to animal studies they say support their allegations.

The families told U.S. District Judge F. Dennis Saylor IV that GlaxoSmithKline LLC’s motion to dismiss all of their more than 200 cases is premature, as no discovery has yet been undertaken, and since the U.S. Food and Drug Administration hasn’t...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In Re: Zofran (Ondansetron)Products Liability Litigation


Case Number

1:15-md-02657

Court

Massachusetts

Nature of Suit

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Judge

F. Dennis Saylor, IV

Date Filed

October 13, 2015

Law Firms

Companies

Government Agencies

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.